Shandong Hyalurpharm Pharmaceutical Co., Ltd., established in August 2012, is a state-controlled enterprise. It serves as a strategic supporting enterprise for the bulk drug sector within the Lushang Group's health industry and for the FURUIDA Pharmaceutical Group's strategy of bulk drug industrialization and integrated formulation production. Additionally, it functions as a strategic platform for transforming new products and technologies from the Shandong Academy of Pharmaceutical Sciences.

The company specializes in anti-inflammatory, analgesic, diabetes, and anesthetic chemical raw materials. It is a modern, national high-tech pharmaceutical enterprise integrating R&D, production, and sales. Located in the Linshu Economic Development Zone (a provincial-level chemical park) in Shandong Province, the project occupies 104 mu (about 6.93 hectares) with a building area of 39,000 square meters.

Committed to innovation-driven development, the company focuses on market demand and product innovation. It operates a Shandong Provincial Enterprise Technology Center and is recognized as a backbone enterprise in chemical synthetic drugs in Shandong. It maintains long-term, stable cooperative relationships with renowned research institutions like the Shandong Academy of Pharmaceutical Sciences and universities such as Shandong University and Linyi University. The company has undertaken over 10 provincial and ministerial-level major scientific and technological projects, holds 14 authorized patents, and has won 3 provincial and ministerial-level science and technology awards. It is recognized as a National High-Tech Enterprise, a Shandong Provincial "Specialized, Refined, Unique, and New" SME, and a Shandong Provincial "Gazelle" Enterprise.

Adhering to green development principles, the company has built 5 advanced bulk drug production lines. It has established a quality assurance system aligned with international regulatory standards such as ICH, EDQM, and PMDA. Its products have passed China's new GMP certification, European CEP, and Japanese PMDA certifications. The company holds 10 registrations for raw materials, excipients, and packaging materials (DMFs), has 8 new products in R&D, and boasts an annual production capacity of 500 tons. Key products include Gliclazide, Amino Azacyclic Hydrochloride (Intermediate), Felbinac, Oxybuprocaine Hydrochloride, Lidocaine, Prilocaine, Tofacitinib Citrate, and Tadalafil. These products are exported to more than 30 countries and regions, including North America, the EU, Japan, South Korea, and Southeast Asia.

Moving forward, Haiyou Freda remains committed to its mission of “Creating a Healthy Ecosystem through Science and Technology,” accelerating the value reshaping of its strategy, business, organization, and culture. By deeply implementing the Group’s “1234” High-Quality Innovation and Development Strategy, the company aims to become a socially trusted and internationally renowned leader in the pharmaceutical and health industry.